| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/07/2003 | CA2047531C 1-(substituted pyridinylamino)-1h-indol-5-yl substituted carbamates, a process and intermediates for their preparation and their use as medicaments |
| 01/06/2003 | CA2392187A1 Combination preparation for the therapy of immunological diseases |
| 01/05/2003 | CA2392189A1 Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents |
| 01/05/2003 | CA2390181A1 Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents |
| 01/03/2003 | WO2003001212A2 A method for diagnosing a person having multiple sclerosis |
| 01/03/2003 | WO2003000896A2 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE |
| 01/03/2003 | WO2003000889A2 Identification of ses-1 and the uses of the same |
| 01/03/2003 | WO2003000886A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/03/2003 | WO2003000871A1 Schwann cells originating in myeloid interstitial cells |
| 01/03/2003 | WO2003000868A1 Dopaminergic neurons and proliferation-competent precursor cells for treating parkinson's disease |
| 01/03/2003 | WO2003000864A2 Nucleic acid-associated proteins |
| 01/03/2003 | WO2003000859A2 G-protein coupled receptors |
| 01/03/2003 | WO2003000849A2 Methods for representing sequence-dependent contextual information present in polymer sequences and uses thereof |
| 01/03/2003 | WO2003000844A2 Protein modification and maintenance molecules |
| 01/03/2003 | WO2003000717A2 Identification of ses-3 (spr-5) in c. elegans and the uses of the same |
| 01/03/2003 | WO2003000709A2 Sialic acid derivatives for use as siglec inhibitors |
| 01/03/2003 | WO2003000699A1 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain |
| 01/03/2003 | WO2003000698A1 β-BENZYLOXYASPARTATE DERIVATIVES WITH AMINO GROUP ON BENZENE RING |
| 01/03/2003 | WO2003000697A1 Furoisoquinoline derivative, process for producing the same, and use |
| 01/03/2003 | WO2003000694A1 6-phenyldihydropyrrolopyrimidinedione derivatives |
| 01/03/2003 | WO2003000693A1 Imidazotriazines for use as phosphodiesterase inhibitors |
| 01/03/2003 | WO2003000691A1 Carboline derivatives as pdev inhibitors |
| 01/03/2003 | WO2003000687A1 Tyrosine kinase inhibitors |
| 01/03/2003 | WO2003000684A1 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 01/03/2003 | WO2003000678A1 Cyanoanthranilamide derivatives and the use thereof as medicaments |
| 01/03/2003 | WO2003000677A1 Spiropiperidine compounds as ligands for orl-1 receptor |
| 01/03/2003 | WO2003000672A1 Process for the preparation of racemic citalopram and/or s- or r-citalopram by separation of a mixture of r- and s-citalopram |
| 01/03/2003 | WO2003000671A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 01/03/2003 | WO2003000670A1 A11-piperazinyldibenzo (b, f) (1, 4) oxazepines and thiazepines as atypical antipsychotic agents having low affinity for the d2 receptor |
| 01/03/2003 | WO2003000668A1 Oxa(thia)zolidine compounds, process for preparation thereof and anti-inflammatory agents |
| 01/03/2003 | WO2003000666A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | WO2003000663A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | WO2003000654A1 Valproyltaurinamide derivatives as anticonvulsant and cns active agents |
| 01/03/2003 | WO2003000323A1 Safety shield system for prefilled syringes |
| 01/03/2003 | WO2003000322A1 Safety shield system for prefilled syringes |
| 01/03/2003 | WO2003000281A1 Neuroprotection and/or neurorestoration via the neural avtivin type iib receptor |
| 01/03/2003 | WO2003000273A1 Modulating serum amyloid a interaction with tanis and agents useful for same |
| 01/03/2003 | WO2003000269A2 Novel use for pde 10a inhibitors |
| 01/03/2003 | WO2003000268A1 Use of na+ channel blockers and aspirin in manufacturing drugs for producing analgesia synergistically in mammals |
| 01/03/2003 | WO2003000261A1 Use of bicyclo compounds for treating alzheimer's disease |
| 01/03/2003 | WO2003000257A1 TGF-ß SUPERFAMILY PRODUCTION/SECRETION PROMOTER |
| 01/03/2003 | WO2003000252A1 5-halo-tryptamine derivatives used as ligands of the 5-ht6 and/or 5-ht7 serotonin receptors |
| 01/03/2003 | WO2003000247A1 Carbamates of 2-heterocyclic-1,2-ethanediols |
| 01/03/2003 | WO2003000240A2 Stable powder inhalation dosage formulation |
| 01/03/2003 | WO2003000238A1 Pharmaceutical compositions of adsorbates of amorphous drug |
| 01/03/2003 | WO2003000185A2 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | WO2003000181A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | WO2003000180A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | WO2003000173A2 Use of branched-chain fatty acids and derivatives thereof for the treatment of pain |
| 01/03/2003 | WO2003000158A1 Pharmaceutical composition |
| 01/03/2003 | WO2003000021A2 Pancam nucleic acids and polypeptides |
| 01/03/2003 | WO2003000018A2 Dopamine agonist formulations for enhanced central nervous system delivery |
| 01/03/2003 | WO2002088101A3 Inhibitors of bace |
| 01/03/2003 | WO2002083667A3 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/03/2003 | WO2002083656A3 5-membered heterocycles, preparation and use thereof as mao inhibitors and lipid peroxidation inhibitors, preparation thereof and use thereof as medicaments |
| 01/03/2003 | WO2002080914A3 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments |
| 01/03/2003 | WO2002072584A3 Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders |
| 01/03/2003 | WO2002072029A3 Dopamine d4 receptor antagonists as treatment for attention deficit-hyperactivity disorder |
| 01/03/2003 | WO2002066020A3 Modulation of gsk-3beta activity and its different uses |
| 01/03/2003 | WO2002056915A3 Complex of modafinil and cyclodextrin |
| 01/03/2003 | WO2002046170A8 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 01/03/2003 | WO2002045702A3 Tricyclic therapeutics for chemokine mediated diseases |
| 01/03/2003 | WO2002034741A3 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 01/03/2003 | WO2002020764A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 01/03/2003 | WO2002012501A3 Anti-dual integrin antibodies, compositions, methods and uses |
| 01/03/2003 | WO2002012500A3 Anti-il-12 antibodies, compositions, methods and uses |
| 01/03/2003 | WO2002010387A3 G-protein coupled receptors |
| 01/03/2003 | WO2002002757A3 Adenylyl and guanylyl cyclases |
| 01/03/2003 | WO2002002603A3 Protein modification and maintenance molecules |
| 01/03/2003 | WO2002000727A3 Gp286 nucleic acids and polypeptides |
| 01/03/2003 | CA2459985A1 Pancam nucleic acids and polypeptides |
| 01/03/2003 | CA2455292A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2451839A1 Pharmaceutical compositions comprising peptides and permeation enhancers |
| 01/03/2003 | CA2451664A1 Use of bicyclo compounds for treating alzheimer's disease |
| 01/03/2003 | CA2451525A1 Imidazotriazines for use as phosphodiesterase inhibitors |
| 01/03/2003 | CA2451486A1 Dopaminergic neurons and proliferation-competent precursor cells for treating parkinson's disease |
| 01/03/2003 | CA2451351A1 A method for diagnosing a person having multiple sclerosis |
| 01/03/2003 | CA2451271A1 Pancam nucleic acids and polypeptides |
| 01/03/2003 | CA2451250A1 Modulating serum amyloid a interaction with tanis and agents useful for same |
| 01/03/2003 | CA2450969A1 Nucleic acid-associated proteins |
| 01/03/2003 | CA2450925A1 G-protein coupled receptors |
| 01/03/2003 | CA2450921A1 Protein modification and maintenance molecules |
| 01/03/2003 | CA2450579A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450562A1 Tyrosine kinase inhibitors |
| 01/03/2003 | CA2450550A1 Spiropiperidine compounds as ligands for orl-1 receptor |
| 01/03/2003 | CA2450491A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2450478A1 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | CA2450475A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2449844A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 01/02/2003 | WO2002002529A1 Bicyclic lactams and sulfonamides with 5-ht1a-affinity and use thereof for preventing and treating cerebral ischaemia |
| 01/02/2003 | US20030004351 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 01/02/2003 | US20030004350 Pyrrolo(2,3-b)pyridine derivatives; anticancer and antiproliferative agents |
| 01/02/2003 | US20030004340 Skin disorders; gastrointestinal disorders |
| 01/02/2003 | US20030004324 31 human secreted proteins |
| 01/02/2003 | US20030004212 Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists |
| 01/02/2003 | US20030004200 Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-YL] benzenesulfonamide |
| 01/02/2003 | US20030004196 Antiinflamamtory agents; autoimmune disease |
| 01/02/2003 | US20030004194 Method for treating fibrotic diseases or other indications VI |
| 01/02/2003 | US20030004193 Immunomodulators; antiinflammatory agents |
| 01/02/2003 | US20030004191 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |